Loss of PP2A and PTEN immunoexpression coexists with survivin overexpression in adenomyosis

article OA: closed CC0 ⤵ 4 in-corpus citations
View on OpenAlex View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-09

This paper investigated the coexistence of survivin overexpression with loss of PP2A and PTEN immunoexpression in adenomyosis tissue.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Phosphatase and tensin homolog (PTEN) and protein phosphatase type 2A (PP2A) are negative modulators of PI3K/AKT/survivin signaling. To evaluate immunoexpression of PTEN, PP2A and survivin in adenomyosis, ectopic lesions from 28 patients with adenomyosis and endometria from 30 controls without adenomyosis were employed in the study. The expression of PTEN, PP2A and survivin was examined with the use of immunohistochemistry. We found a decreased expression of PP2A and PTEN in adenomyosis. The expression of PTEN showed great individual differences in adenomyosis, although expression of both PP2A and PTEN was lower in adenomyosis than in normal endometria. In contrast, the expression of survivin was higher in adenomyosis. Our results suggest the important role of the PI3K cascade in the pathogenesis and development of adenomyosis.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Down-Regulation Endometrium Inhibitor of Apoptosis Proteins Protein Phosphatase 2 PTEN Phosphohydrolase Up-Regulation Adenomyosis Adenomyosis Adult Algorithms Endometrium Endometrium Endometrium Female Humans Immunohistochemistry Inhibitor of Apoptosis Proteins Phosphatidylinositol 3-Kinase Phosphatidylinositol 3-Kinase

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

Cited by (4)

References (36)

Cited by (4)

Source provenance

europepmc
last seen: 2026-08-02T06:10:09.037253+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:18:15.805398+00:00
License: CC0 · commercial use OK